Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Retinopathy (2 trials), Macular Edema (2 trials)
- Main trialPhase 3
- “Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.”In the company’s words, NCT07705555 on ClinicalTrials.gov
- Other names
- EYE201 · Tiespectus
Other drugs for Diabetic Retinopathy
- Surabgene LomparvovecAbbVie · Phase 2/3
- OLN324Ollin Biosciences, Inc. · Phase 3
- BI 764524Boehringer Ingelheim · Phase 2
- VX-01Vantage Biosciences Ltd · Phase 2
- BGE-102BioAge Labs · Phase 2
- 4D-150 IVT4D Molecular Therapeutics · Phase 2
Coming up2
- 31 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Oct 2028 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) | |
| Phase 3Recruiting | 30 Nov 2028 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026